CompletedNot Applicable

A Pilot RCT of Veraflo With Prontosan vs VAC in Wounds Requiring Operative Debridement

United States181 participantsStarted 2013-05

Plain-language summary

The purpose of this study is to examine the effectiveness of the Veraflo with Prontosan vs VAC in wounds that require operative debridement.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. malignancy in the wound
✕. untreated osteomyelitis
✕. non-enteric or unexplored fistulas
✕. necrotic tissue with eschar remaining in the wound after debridement (NOTE: Once necrotic tissue or eschar is removed from the wound bed, subjects may be included)
✕. unprotected, exposed blood vessels, anastomotic sites, organs, or nerves in direct contact with foam
✕. Thoracic or abdominal cavities
✕. Unexplored wounds that may communicate with adjacent body cavities

Number of Inpatient Operating Room Debridements

Timeframe: until the wound is deemed ready for closure or coverage by the investigator up to 64 days

NCT IDNCT01867580

SponsorKCI USA, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-08

Results submitted2017-06-07